Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_assertion type Assertion NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_head.
- NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_assertion description "[IFN-free regimens with direct antiviral agents (DAAs) against hepatitis C virus (HCV) are likely to greatly expand patients' access and response to hepatitis C therapy, while safety and tolerability of treatments seem substantially improved.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_provenance.
- NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_assertion evidence source_evidence_literature NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_provenance.
- NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_assertion SIO_000772 25645644 NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_provenance.
- NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_assertion wasDerivedFrom befree-2016 NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_provenance.
- NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_assertion wasGeneratedBy ECO_0000203 NP1260437.RAc2ofvS1-EYsNJ4n7M5Mb8WmuQIkbEUS6dF9ehNFEM1I130_provenance.